Literature DB >> 30218474

The prevalence of computed tomography-defined leaflet thrombosis in intra- versus supra-annular transcatheter aortic valve prostheses.

Hashrul N Rashid1, Arthur Nasis1, Robert P Gooley1, James D Cameron1, Adam J Brown1.   

Abstract

INTRODUCTION: Leaflet thrombosis (LT) defined by computed tomography (CT) following transcatheter aortic valve replacement (TAVR) has been shown to increase cerebrovascular events. The neo-sinus plays an important role in the development of LT. Intra-annular valves (IAV) have a larger neo-sinus when compared to supra-annular valves (SAV), and has been associated with larger thrombus burden. The prevalence of LT with IAV and SAV in a larger, diverse cohort is unknown.
METHODS: We performed a systematic review to assess the prevalence of LT in IAV versus SAV TAVR prostheses. Inclusion criteria were (1) reported CT-defined LT following TAVR, (2) comparison between LT and non-LT cohort, (3) separate registry/database, and (4) fully published status. A total of 2,013 citations were reviewed and 7 studies were included.
RESULTS: Overall, 1,644 patients were included from 7 observational studies and the prevalence of LT following TAVR was 12.8%. The Portico valve system (IAV) had the highest prevalence of LT with 35.2%, followed by Symetis Acurate Neo (SAV) at 15.4% and the Lotus valve system (IAV) at 14.5%. LT occurred more frequently in IAV than SAV (13.5% vs. 7%, P = 0.02). Subanalysis of IAV versus SAV with the exclusion of the Portico valve was performed to ensure results were not influenced by this valve system and revealed IAV still had higher rates of LT (12.1% vs. 7%, P = 0.05).
CONCLUSION: In summary, IAV prostheses appear to be associated with higher rates of LT when compared with SAV.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  aortic stenosis; aortic valve disease; leaflet thrombosis; transcatheter aortic valve replacement

Mesh:

Year:  2018        PMID: 30218474     DOI: 10.1002/ccd.27702

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

Review 1.  How to Image and Manage Prosthesis-Related Complications After Transcatheter Aortic Valve Replacement.

Authors:  Nina C Wunderlich; Jörg Honold; Martin J Swaans; Robert J Siegel
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 2.  Clinical valve thrombosis and subclinical leaflet thrombosis in transcatheter aortic heart valves: clinical manifestations, diagnosis, and treatment.

Authors:  Liesbeth Rosseel; Ole De Backer; Lars Søndergaard
Journal:  Precis Clin Med       Date:  2018-12-05

3.  Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.

Authors:  Hanbit Park; Do-Yoon Kang; Jung-Min Ahn; Kyung Won Kim; Anthony Y T Wong; Simon C C Lam; Wei-Hsian Yin; Jeng Wei; Yung-Tsai Lee; Hsien-Li Kao; Mao-Shin Lin; Tsung-Yu Ko; Won-Jang Kim; Se Hun Kang; Euihong Ko; Dae-Hee Kim; Hyun Jung Koo; Dong Hyun Yang; Joon-Won Kang; Seung Chai Jung; Jae-Hong Lee; Sung-Cheol Yun; Seung-Jung Park; Duk-Woo Park
Journal:  BMJ Open       Date:  2021-01-05       Impact factor: 2.692

4.  The role of four-dimensional computed tomography in transcatheter aortic valve replacement prosthesis endocarditis with concurrent leaflet thrombosis: a case report.

Authors:  Nancy Khav; Hashrul N Rashid; Adam J Brown
Journal:  Eur Heart J Case Rep       Date:  2020-09-04

Review 5.  Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?

Authors:  Liesbeth Rosseel; Ole De Backer; Lars Søndergaard
Journal:  Front Cardiovasc Med       Date:  2019-04-18

6.  Added value of 18F-FDG-PET/CT and cardiac CTA in suspected transcatheter aortic valve endocarditis.

Authors:  Ali R Wahadat; Wilco Tanis; Laurens E Swart; Asbjørn Scholtens; Gabriel P Krestin; Nicolas M D A van Mieghem; Carolina A M Schurink; Tycho I G van der Spoel; Floris S van den Brink; Tessel Vossenberg; Riemer H J A Slart; Andor W J M Glaudemans; Jolien W Roos-Hesselink; Ricardo P J Budde
Journal:  J Nucl Cardiol       Date:  2019-12-02       Impact factor: 5.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.